American Well Corporation (NYSE:AMWL) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET
Company Participants
Sue Dooley - Head of Investor Relations
Ido Schoenberg - Chairman & Co-Chief Executive Officer
Bob Shepardson - Chief Financial Officer
Conference Call Participants
Lucas Romanski - Cowen
Matthew Shea - Needham & Company
Craig Hettenbach - Morgan Stanley
Jack Wallace - Guggenheim Securities
Hanna Lee - Bank of America
Dolph Warburton - Nephron Research
David Larsen - BTIG
Operator
Good evening. My name is Savannah and I will be your conference operator for today. At this time, I would like to welcome everyone to the Amwell Q4 2022 Earnings Call. [Operator Instructions] Thank you.
And I would now like to hand the call over to Sue Dooley, Head of Investor Relations of Amwell. You may begin.
Sue Dooley
Hello, everyone. Welcome to Amwell's conference call to discuss our fourth fiscal quarter and year-end of 2022. This is Sue Dooley of Amwell Investor Relations. And joining me today are Amwell's Chairman and CEO, Dr. Ido Schoenberg; and Bob Shepardson, our CFO. Earlier today, we distributed a press release detailing our announcement. This release is posted on our website at investors.amwell.com and is also available from normal news sources. This conference call is being webcast live on the IR page of our website where a replay will be archived.
Before we begin our prepared remarks, I'd like to take this opportunity to remind you that during the course of this call, we will make forward-looking statements regarding projected operating results and anticipated market opportunities. This forward-looking information is subject to the risks and uncertainties described in our filings with the SEC and actual results or events may differ materially. Except as required by law, we undertake no obligation to update or revise these forward-looking statements. On this call, we'll refer to both GAAP and non-GAAP financial measures. A reconciliation of our GAAP to non-GAAP financial measures is provided in our posted earnings release.
With that, I would like to turn the call over to Ido.
Ido Schoenberg
Thank you, Sue and hello, everyone. I'm pleased to report that in Q4, we successfully capped off an important and strategic year for Amwell. On many levels, it was an incredible year. We rallied as a company and executed well, making meaningful progress in the transition to Converge, our software platform that we believe will enable and empower the future of hybrid care and which has already been embraced and implemented by some of the most demanding and innovative health care organizations.